News
The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...
FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma
Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...
Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...
Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results